BioCryst Pharmaceuticals, Inc. announced that it has completed its acquisition of Astria Therapeutics, Inc., initially announced on October 14, 202...
Antibodies Inc., a leading supplier of validated life science research reagents, announced the availability of its Recombinant Guinea Pig RBPMS An...
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecos...
Ant Group announced a major upgrade to the PC platform of its AI-native health assistant, AQ, introducing DeepSearch for clinicians, a new capabili...
Parse Biosciences and Graph Therapeutics (Graph) announced a strategic partnership to create one of the largest and most comprehensive immune cell pertur...
The phase 3 trial DELTA CARE 1 will recruit up to 652 adult patients with lichen sclerosus (LS) to investigate the efficacy and safety of delgocitini...
-Bayer and Vanderbilt University Medical Center (VUMC) announced that they have entered a strategic five-year collaboration agreement to advance innovati...
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA...
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced that the Company has decided to voluntarily withdraw the biologics...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, announced updated efficacy and safety results from the ongoing QUILT-106 clin...
Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps Ge...
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced that th...
Ouroboros Family Founders Fund I, LP announced this week it will lead a $60 million Series A financing in Cytotheryx, Inc., a preclinical cell therapy comp...
Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss ...
© 2026 Biopharma Boardroom. All Rights Reserved.
